134 related articles for article (PubMed ID: 1694132)
1. Down-regulation of CD5 mRNA in B-chronic lymphocytic leukemia cells by differentiation-inducing agents.
Gignac SM; Buschle M; Hoffbrand AV; Drexler HG
Eur J Immunol; 1990 May; 20(5):1119-23. PubMed ID: 1694132
[TBL] [Abstract][Full Text] [Related]
2. Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro.
al-Katib A; Mohammad RM; Dan M; Hussein ME; Akhtar A; Pettit GR; Sensenbrenner LL
Exp Hematol; 1993 Jan; 21(1):61-5. PubMed ID: 8093352
[TBL] [Abstract][Full Text] [Related]
3. Synergistic action of calcium ionophore A23187 and protein kinase C activator bryostatin 1 on human B cell activation and proliferation.
Drexler HG; Gignac SM; Pettit GR; Hoffbrand AV
Eur J Immunol; 1990 Jan; 20(1):119-27. PubMed ID: 1689659
[TBL] [Abstract][Full Text] [Related]
4. Expression of proto-oncogene c-jun during differentiation of B-chronic lymphocytic leukemia.
Gignac SM; Buschie M; Pettit GR; Hoffbrand AV; Drexler HG
Leukemia; 1990 Jun; 4(6):441-4. PubMed ID: 2113601
[TBL] [Abstract][Full Text] [Related]
5. Response of Jurkat T cells to phorbol ester and bryostatin. Development of sublines with distinct functional responses and changes in protein kinase C activity.
Levine BL; May WS; Tyler PG; Hess AD
J Immunol; 1991 Nov; 147(10):3474-81. PubMed ID: 1834742
[TBL] [Abstract][Full Text] [Related]
6. Effects of bryostatins 1 and 2 on morphological and functional differentiation of SH-SY5Y human neuroblastoma cells.
Jalava AM; Heikkilä J; Akerlind G; Pettit GR; Akerman KE
Cancer Res; 1990 Jun; 50(11):3422-8. PubMed ID: 2334938
[TBL] [Abstract][Full Text] [Related]
7. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.
Grant S; Turner AJ; Freemerman AJ; Wang Z; Kramer L; Jarvis WD
Exp Cell Res; 1996 Oct; 228(1):65-75. PubMed ID: 8892972
[TBL] [Abstract][Full Text] [Related]
8. Human interleukin 4 down-regulates the surface expression of CD5 on normal and leukemic B cells.
Defrance T; Vanbervliet B; Durand I; Banchereau J
Eur J Immunol; 1989 Feb; 19(2):293-9. PubMed ID: 2467815
[TBL] [Abstract][Full Text] [Related]
9. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells.
Wang Z; Su ZZ; Fisher PB; Wang S; VanTuyle G; Grant S
Exp Cell Res; 1998 Oct; 244(1):105-16. PubMed ID: 9770354
[TBL] [Abstract][Full Text] [Related]
10. Expression of CD5 and CD38 by human CD5- B cells: requirement for special stimuli.
Zupo S; Dono M; Massara R; Taborelli G; Chiorazzi N; Ferrarini M
Eur J Immunol; 1994 Jun; 24(6):1426-33. PubMed ID: 7515814
[TBL] [Abstract][Full Text] [Related]
11. Cellular activation without proliferation to B cell growth factor and interleukin 2 in chronic lymphocytic leukaemia B cells stimulated with phorbol ester plus calcium ionophore.
Engel P; Inglés J; de la Calle O; Gallart T
Clin Exp Immunol; 1989 Apr; 76(1):61-7. PubMed ID: 2500274
[TBL] [Abstract][Full Text] [Related]
12. Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells.
Drexler HG; Gignac SM; Jones RA; Scott CS; Pettit GR; Hoffbrand AV
Blood; 1989 Oct; 74(5):1747-57. PubMed ID: 2506950
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase inhibitor, staurosporine, induces a mature neuronal phenotype in SH-SY5Y human neuroblastoma cells through an alpha-, beta-, and zeta-protein kinase C-independent pathway.
Jalava A; Akerman K; Heikkilä J
J Cell Physiol; 1993 May; 155(2):301-12. PubMed ID: 8482723
[TBL] [Abstract][Full Text] [Related]
14. Differences in constitutive and activation-induced expression of CD69 and CD95 between normal and chronic lymphocytic leukemia B cells.
De Fanis U; Romano C; Dalla Mora L; Sellitto A; Guastafierro S; Tirelli A; Bresciano E; Giunta R; Lucivero G
Oncol Rep; 2003; 10(3):653-8. PubMed ID: 12684639
[TBL] [Abstract][Full Text] [Related]
15. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.
Ahmad I; Al-Katib AM; Beck FW; Mohammad RM
Clin Cancer Res; 2000 Apr; 6(4):1328-32. PubMed ID: 10778958
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional regulation of CD6 expression on human T lymphocytes by phorbol ester.
Bott CM; Doshi JB; Li LL; McMurtry SA; Sanders JL; Fox DA
J Immunol; 1994 Jul; 153(1):1-9. PubMed ID: 8207228
[TBL] [Abstract][Full Text] [Related]
17. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
[TBL] [Abstract][Full Text] [Related]
18. Expression and regulation of CD5 on in vitro activated human B cells.
Freedman AS; Freeman G; Whitman J; Segil J; Daley J; Levine H; Nadler LM
Eur J Immunol; 1989 May; 19(5):849-55. PubMed ID: 2472277
[TBL] [Abstract][Full Text] [Related]
19. Modulation of gene expression in the acute promyelocytic leukemia cell line NB4.
Hu ZB; Ma W; Uphoff CC; Lanotte M; Drexler HG
Leukemia; 1993 Nov; 7(11):1817-23. PubMed ID: 7901456
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C.
Isakov N; Galron D; Mustelin T; Pettit GR; Altman A
J Immunol; 1993 Feb; 150(4):1195-204. PubMed ID: 8432975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
